Humacyte Future Growth
Future criteria checks 2/6
Humacyte is forecast to grow earnings and revenue by 48.1% and 66.4% per annum respectively while EPS is expected to grow by 51.1% per annum.
Key information
48.1%
Earnings growth rate
51.1%
EPS growth rate
Biotechs earnings growth | 30.1% |
Revenue growth rate | 66.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 14 Aug 2024 |
Recent future growth updates
Recent updates
Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Aug 16Humacyte: Pioneering Vascular Solutions With High-Stakes Potential
Jul 17Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation
Jun 05Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High
May 14Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Feb 14Humacyte: Intriguing Potential
Oct 13Humacyte GAAP EPS of $0.35, revenue of $1.3M
Aug 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 86 | -71 | -60 | N/A | 4 |
12/31/2025 | 18 | -115 | -43 | -107 | 5 |
12/31/2024 | 0 | -136 | N/A | -106 | 5 |
6/30/2024 | N/A | -140 | -82 | -81 | N/A |
3/31/2024 | N/A | -106 | -84 | -82 | N/A |
12/31/2023 | N/A | -111 | -76 | -73 | N/A |
9/30/2023 | N/A | -89 | -76 | -73 | N/A |
6/30/2023 | 0 | -89 | -80 | -77 | N/A |
3/31/2023 | 1 | -29 | -73 | -71 | N/A |
12/31/2022 | 2 | -12 | -72 | -71 | N/A |
9/30/2022 | 2 | 34 | -74 | -74 | N/A |
6/30/2022 | 2 | 28 | -88 | -87 | N/A |
3/31/2022 | 1 | -26 | -86 | -85 | N/A |
12/31/2021 | 1 | -26 | -81 | -81 | N/A |
9/30/2021 | 1 | -85 | -75 | -75 | N/A |
6/30/2021 | 2 | -71 | -57 | -57 | N/A |
3/31/2021 | 1 | -69 | -54 | -54 | N/A |
12/31/2020 | 1 | -67 | -56 | -56 | N/A |
12/31/2019 | 6 | -85 | -80 | -72 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HUMA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HUMA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HUMA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HUMA's revenue (66.4% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: HUMA's revenue (66.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HUMA's Return on Equity is forecast to be high in 3 years time